Cargando…
Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
A recent prospective clinical trial provides further evidence that breast cancers arising in germline BRCA1 mutation carriers are highly sensitive to cisplatin chemotherapy. The potential significance of these data for the management of patients with BRCA1-related and BRCA2-related breast cancer is...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053124/ https://www.ncbi.nlm.nih.gov/pubmed/23146216 http://dx.doi.org/10.1186/bcr3332 |